Evidence map›Paper›PMID 39352544›Full record

ReviewCellular and molecular life sciences : CMLS2024

A review and perspective paper: Ras oncogene gets modest, from kingpin to mere henchman.

Jacques H Camonis, Vasily N Aushev, Elina Zueva, Gérard Zalcman

Abstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jacques H CamonisInstitut Curie, Inserm U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005, Paris, France. jacquescamonis@gmail.com.ORCID http://orcid.org/0000-0003-2047-4150
Vasily N AushevNatera Inc, San Carlos, CA, 94070, USA.ORCID http://orcid.org/0000-0001-8003-358X
Elina ZuevaInstitut Curie, Inserm U932, Université PSL, 75005, Paris, France.ORCID http://orcid.org/0000-0002-6276-5127
Gérard ZalcmanUniversité Paris Cité, Thoracic Oncology Department, Hôpital Bichat, AP-HP.Nord & U830 Inserm Stress and Cancer Laboratory, Institut Curie, 26 rue d'Ulm, 75005, Paris, France.ORCID http://orcid.org/0000-0002-0343-9575

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The concomitant activation of both the YAP1 co-transcription factor and RAS GTPases is a hallmark of several aggressive cancers, though the intricacies of their relationship and implications for oncogenesis are still poorly understood. This review has presented a cooperative model where YAP1 and RAS are not independently acting oncogenes but rather interdependently acting ones, with each fulfilling an essential role within the oncogenic process. YAP1 is responsible for initiating the expression of key proteins that contribute to various cancer traits. However, these proteins must often be transported into the cytoplasm to exert their effects. We suggest that oncogenic RAS actually facilitates this transport, enabling the phosphorylation and subsequent activation of the nuclear transporter XPO1 (aka Exportin1). This mechanism is particularly crucial for anti-apoptotic proteins. Instead of being sequestered within the nucleus in an ineffective state, these proteins are rather shuttled into the cytoplasm. Within the cytoplasm, they can effectively inhibit apoptosis, undermining by these means the efficacy of chemotherapeutic agents designed to induce cell death in cancer cells. Therefore, a clearer understanding of the oncogenic partnership between RAS and YAP1 will likely provide new insights into the molecular underpinnings of cancer and highlight as well potential targets for therapeutic interventions designed to disrupt this pernicious interaction.

Indexed as

Transcription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingAnimalsApoptosisExportin 1 ProteinGenes, rasHumansKaryopherinsNeoplasmsPhosphoproteinsras ProteinsReceptors, Cytoplasmic and NuclearAdaptor Proteins, Signal TransducingExportin 1 ProteinKaryopherinsPhosphoproteinsras ProteinsReceptors, Cytoplasmic and NuclearTranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsCancer therapyNuclear-cytoplasmic transportRAS oncogeneSpatial control of oncogenesisYAP1 co-transcription factor

Identifiers

PMID39352544
PMCPMC11445209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.